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In clinical practice, the operator must decide which stent is most appropriate for the patient.
This article focuses on the features of stent design that make a specific stent more or less
suitable for a particular type of lesion or anatomy: the “average” coronary lesion, the lesion
situated on a curve, the ostial lesion, the bifurcational lesion, the lesion located at the left main
stem, the calcified lesion, the chronic total occlusion, the small vessel, the saphenous vein
graft, acute or threatened vessel closure, and special situations such as coronary aneurysms and
perforations. (J Am Coll Cardiol 2002;40:1021–33) © 2002 by the American College of
Cardiology Foundation
The implantation of coronary stents is an integral part of
most interventional procedures for percutaneous revascular-
ization. The wide acceptance of coronary stenting was based
on the results of the BElgian NEtherlands STENT (BE-
NESTENT) (1) and the STent REStenosis Study
(STRESS) (2) trials and was facilitated by the elimination
of anticoagulant therapy after stent implantation (3–5).
The growing use of stents has stimulated the introduction
of a number of different stent designs. Table 1 illustrates the
characteristics of most of the stents available in 2002. The
rapid increase in the number of designs makes any list
quickly outdated. Some stent designs are similar, whereas
others differ significantly. There are many reasons why
different designs have been proposed. Besides the legal
requirement to overcome a specific patent, there are con-
cepts of physiologic mechanisms that stimulated inventors
to introduce new designs. A primary concern of stent
development was the need to increase flexibility to facilitate
safe delivery. Manufacturers try to achieve this goal without
compromising radial support and lesion coverage. Another
element important for optimizing the clinical utility of a
stent is its radiologic visibility.
Many of the engineering considerations in stent design
were adopted to improve the global acceptability of the
device, rather than making a stent design for a specific type
of coronary lesion. In clinical practice, the operator must
decide which stent is most appropriate for the patient. This
article focuses on the features of stent design that make a
specific stent more or less suitable for a particular type of
lesion or anatomy.
Types of stents. Stents can be classified according to their
mechanism of expansion (self-expanding or balloon-
expandable), their composition (stainless steel, cobalt-based
alloy, tantalum, nitinol, inert coating, active coating, or
biodegradable), and their design (mesh structure, coil,
slotted tube, ring, multi-design, or custom design) (Table
1). According to the manufacturers, all stents are suitable for
implantation in native coronary arteries of the appropriate
size. Some stents are approved for implantation in vein
grafts. Few stents are specifically designed to be implanted
in a particular lesion. The absolute or relative contraindica-
tions to the use of stents apply to stents in general and not
to a specific stent. Possible exceptions are the Multilink
Ultra Stent (Guidant, Temecula, California), which is
designed for vein graft implantation with a nine-cell design,
by contrast with the six-cell design of the Multilink Tetra.
The JoMed polytetrafluoroethylene (PTFE)-covered stent
(JoMed, Rangendingen, Germany) is specifically made for
uncommon applications such as coronary ruptures, aneu-
rysms, and degenerated saphenous vein grafts.
Different characteristics such as strut thickness, metal to
artery ratio, degree of radiopacity, degree of foreshortening,
and recoil of many currently used stents are shown in Table
1. All stents are now available premounted on a dedicated
delivery system. The capacity of a stent to span a lesion
depends not only on the diameter of the crimped stent
(Table 2), but also on the amount of friction of the delivery
system and stent, flaring of the distal struts during interac-
tion with the lesion, flexibility of the stent and of the
delivery balloon, and pushability of the delivery system. It is
not surprising to observe a stent with a larger crossing
profile cross a lesion easier than a narrower stent with less
flexibility.
Two interesting findings came from the stent versus stent
randomized trials: 1) the GR-II stent (Cook, Bloomington,
Indiana) proved clearly inferior—as far as early complica-
tions, binary restenosis, and target lesion revascularization
rate—to the Palmaz-Schatz stent (Cordis, a Johnson &
Johnson Company, Warren, New Jersey) (6); and 2) the
performance of the various other stents and the associated
clinical outcome were not different from the Palmaz-Schatz
stent. The slightly better deliverability of some stents
compared with the Palmaz-Schatz stent, as seen in some of
equivalency trials, has now only historical value. Stents used
nowadays perform significantly better than any of the
early-generation devices.
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Based on our experience with multiple stent systems, we
submit the following observations concerning the applica-
tion of different stents for specific lesion subsets.
The “average” coronary lesion. Stents were initially indi-
cated for proximal, non-angulated lesions, whereas subse-
quent generation stents were developed for lesions of
tortuous anatomy and complex situations. Some stents are
more flexible than others or have a smaller profile and
therefore are more deliverable. These extra features become
necessary only in selected situations. Most stents currently
available are suitable for the majority of coronary lesions,
with some exceptions.
The stents to be used in the “average” coronary lesion are
the new slotted, tubular stents and some new designs of ring
stents.
The primary goal for stenting most coronary lesions is to
achieve the optimal lumen cross-sectional area without
traumatizing the artery. Currently, the achievement of a
large final lumen diameter is the most secure means of
limiting restenosis (7). Other appropriate concerns for stent
choice are adequate lesion coverage, minimal recoil, and
limited plaque prolapse. In addition, because stent length is
an independent predictor of restenosis, it is preferable to
avoid the use of excessive metal (8,9).
The Palmaz-Schatz stent led the way but now has passed
the baton to the BxVelocity (Cordis), as demonstrated in
the Very Early Nimopidine Use in Stroke (VENUS) trial, a
multicenter registry of the Cordis BxVelocity stent (10). It
is likely that the BxVelocity stent will be replaced by the
sirolimus-coated BxVelocity (11,12). The BxVelocity stent
is applicable for everyday use, and there are only a few
conditions in which this stent may not be satisfactory. The
BxVelocity stent is available in three different patterns of
cells according to the vessel size in which the stent will be
implanted: six cells for vessels up to 3 mm, seven cells for
vessels up to 4 mm, and nine cells for vessels up to 5 mm.
The new version, BxSonic (Cordis), has the same stent
mounted on an improved delivery system that is compatible
with the 5F guiding catheter (lower profile proximal hypo-
tube shaft, 1.9F vs. 2.6F shaft of the BxVelocity, and
0.5-mm balloon overhang on each side).
The heparin-coated Palmaz-Schatz stent had a low
incidence of subacute stent thrombosis, with only five
thrombotic events (0.4%) in 1,169 patients treated with this
stent in the following trials: the BENESTENT II pilot
study (13), BENESTENT II randomized study (14), and
the Total Occlusion Study of CAnada (TOSCA) (15), as
well as in two protocols involving patients with acute
myocardial infarction: the stenting in Primary Angioplasty
in Myocardial Infarction (PAMI) pilot study (16) and the
stent PAMI randomized study (17). A multicenter feasibil-
ity study (use of the Hepacoat BxVelocity stent and an
antithrOmbotic regimen of asPirin alonE [HOPE]) is
under way to examine the safety of the heparin-coated
BxVelocity stent (Hepacoat, Cordis) in “low-risk” patients
treated with antiplatelet therapy consisting of only aspirin.
The initial results in 202 patients showed no acute stent
thrombosis and a rate of 1% of subacute thrombosis (one
patient with thrombocytosis and one with post-trauma)
(18).
The Multilink Tetra stent (Guidant) has functional
characteristics that are similar to the BxVelocity stent. The
overall performance of these two stents is excellent, with
only selected situations where the Tetra appears to be more
deliverable. A unique feature of the Tetra delivery system
(similar to the Ultra) is its shaft length of 143 cm, which is
3 cm longer than the BxVelocity stent, whereas all the other
delivery systems are 138 or 135 cm long. Compared with
the Multilink Tetra stent, the Multilink Penta stent
(Guidant) has a modified link pattern, which improves
flexibility and scaffolding and maintains side-branch access
with the possibility to expand the cell toward the side
branch up to 4 mm in diameter.
The careful observer may find more stent-to-vessel con-
formability with the Tetra stent, but no one knows whether
this feature has any clinical consequences. Preserving the
original shear stress pattern of the arterial segment may
lower the amount of tissue hyperplasia (19).
The NIR stent (Medinol, Jerusalem, Israel; and Scimed,
Boston Scientific, Maple Grove, Minnesota), with its new
“sox” delivery system, is another important stent to be
considered for the “average” lesion. The NIR stent provides
excellent plaque coverage, which may be an advantage in
lesions prone to plaque prolapse. Plaque may prolapse
between stent struts in large vessels with a reference diam-
eter 4 mm. The NIR stent is available with a seven-cell or
nine-cell structure, which improves plaque support in large
vessels, including saphenous vein grafts. The sox delivery
system protects the stent while negotiating through calcified
lesion or crossing another stent. These features are unique to
this type of stent delivery system.
The performance of this stent was evaluated against the
Palmaz-Schatz stent in the NIR Vascular Advanced North
American (NIRVANA) trial randomized study (20). This
trial reported a follow-up restenosis rate of 19.3% for the
NIR stent and 22.4% for the Palmaz-Schatz stent. The
moderate rigidity of the NIR stent discourages its use
through tortuous segments and for lesions located at a
severe bend. Because the NIR stent becomes rigid on
deployment, this stent may produce a hinge effect that is
associated with an increase in restenosis (21). Figure 1
demonstrates the hinge effect caused by the NIR stent. This
lesion restenosed four months later at the distal extremity of
the stent (Fig. 2). The operator should foresee this possi-
Abbreviations and Acronyms
IVUS  intravascular ultrasound
PTFE  polytetrafluoroethylene
PTCA  percutaneous transluminal coronary angioplasty
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bility and select a more flexible type of stent in lesions with
a small radius of curvature.
The positive features of these three stents are also related
to the delivery balloon: 1) there is now near perfect
retention, which has eliminated the problem of stent loss; 2)
there is minimal overhang of the delivery balloon from the
stent, which limits trauma and the risk of peri-stent dissec-
tion; and 3) there is low compliance, which assures a more
homogeneous stent deployment (Fig. 3).
The beStent (Medtronic AVE, Minneapolis, Minnesota)
and now the beStent 2, with a closer strut design, are other
stents to consider. The unique feature of this stent is the
presence of proximal and distal gold markers that allow very
precise placement. Another positive feature of the beStent,
but not the beStent 2, is the presence of a large or open cell
design that facilitates access to side branches.
The Biodivysio stent (Biocompatibles, Galway, Ireland)
is another sturdy device with optimal scaffolding that can be
considered for most lesions. This stent is available also with
an open-cell design that is suitable for lesions involving the
origin of side branches. Compared with the open-cell
design, the added support design has an extra strut between
interlocking arrowheads, which provides greater coverage
for lesions that require additional support.
The Biodivysio stent was recently evaluated against the
Duet stent (Guidant) in a randomized trial (bioDIvysio
STent IN randomized Control Trial [DISTINCT]). Both
stents showed an excellent low restenosis rate of 19% in
selected favorable lesions. The standard Biodivysio stent
delivery system appears to be more rigid compared with
other stents and is not ideal for very tortuous arteries. New
versions of the delivery system will soon be released to
overcome this potential limitation. The availability of a
small-vessel design with this stent, which is very trackable
and has a low profile, should be kept in mind when
confronted with complex anatomy. A unique feature of the
Biodivysio family is their phosphorylcholine coating, which
lowers platelet adhesion to the stent struts and may be used
as a platform for drug delivery.
Among the ring stents, the new S7 (Medtronic AVE)
provides more plaque coverage than the S670 and has an
angiographic appearance very similar to the slotted, tubular
stents. This stent is appropriate for most lesions. In addi-
tion, the flexibility, conformability, and lower friction typ-
ical of the S7 ring design improves deliverability in complex
anatomies or when passing through a stent. An important
characteristic of the AVE delivery system is minimal bal-
loon overhang (Fig. 3).
Among the stainless-steel stents with a good track record,
the family of stents from PURA (Devon Medical, Ham-
burg, Germany) and the V-Flex plus (Cook) should be
mentioned.
To make the choice more difficult, the interventionist is
confronted with other excellent stents such as the Sorin
Sirius Carbostent (Sorin Biomedica Cardio, Saluggia, Italy),
with its recently refined delivery system (Sorin Syncro
Carbostent). This stent performs quite well in difficult
anatomies and lesions, has platinum end markers, and is
covered with a thin layer of turbostratic carbon with the
intent to decrease its interaction with platelets. A recent
registry report showing a restenosis rate of 11% and a
bimodal distribution of the loss index (22) raises the
possibility of enhanced biocompatibility of the carbon-
coated stent for subjects with an allergy to metal compo-
nents present in stainless steel (23). At least four other
carbon-coated stents are currently available in Europe: the
BioDiamond (Plasma Chem, Mainz, Germany), the Dia-
mond Flex (Phytis, Dreieich, Germany), the MAC carbon
stent (AMG, Raesfeld-Erle, Germany), and the Tenax
(Biotronik, Berlin, Germany). Randomized trials are in
progress to test the hypothesis that these inertly coated
stents may have advantages over the stainless-steel stents.
Lesions situated on a curve (>90°) or immediately fol-
lowed by a curve. Changing the natural conformation of a
coronary vessel may have an unfavorable effect on flow
dynamics and increase the risk of adverse events during
follow-up (24).
For this reason, we prefer stents that conform to the
longitudinal profile of the vessel without producing plaque
prolapse in the curved segment. The traditional ring design,
such as the S670, is quite conformable but may allow too
much plaque protrusion when opened in a curved segment.
In this respect, the new S7 is a significant improvement.
Slotted, tubular stents with thin struts are also conformable
(PURA AS and AL 0.07, 0.075-mm beStent, 0.075-mm
Sorin Carbostent, 0.08-mm Tenax, 0.09-mm Biodivysio,
and 0.09-mm JoStent). Strut thickness is not the only
variable that may affect conformability; the complete stent
design may be more important. For example, the NIR stent,
which is thinner (0.1 mm) than the BxVelocity (0.14 mm),
has lower conformability. The Tetra and Penta stents have
variable strut thicknesses (0.091–0.124 mm), with excellent
conformability. The NIRflex, the new version of the NIR
stent, also has excellent conformability.
Ostial lesions. Ostial lesions are classified as either aorto-
ostial or coronary-ostial. For aorto-ostial lesions, the
slotted-tube design, preferably with strong radial support,
low recoil, and radiologic visibility, is the most appropriate
one (25). New ring designs such as the S670 and S7 are also
appropriate in this setting.
The recent availability of stents with end markers may
improve precise positioning. These stents have thin struts,
so our preference is to implant them only in coronary-ostial
rather than aorto-ostial locations. The strong elastic recoil
inherent to the aorta favors the use of thicker struts to
provide greater resistance when dealing with lesions involv-
ing the true coronary ostia or the aortic insertion of a
saphenous vein graft.
When considering the gold-plated NIR Royal for an
aorto-ostial lesion, the operator must balance its advantage
of better visibility and more precise positioning with its
disadvantage of having a higher angiographic restenosis rate
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Table 1. Stent Engineering Data
Product Manufacturer Structure Material
Strut (Wire)
Thickness
(mm)
Metal/Artery
(%)*
Recoil
(%)
Shortening
(%) Radiopacity Markers Lengths (mm) Diameters (mm)
AVE S670 Medtronic Sinusoidal ring Stainless steel 0.127 19 3 3 Medium No 9, 12, 15, 18, 24, 30 3.0, 3.5, 4.0
AVE S7 Medtronic Sinusoidal ring Stainless steel 0.102 17–23 2 3 Medium No 9, 12, 15, 18, 24, 30 3.0, 3.5, 4.0
beStent 2 Medtronic Slotted tube Stainless steel 0.085–0.095 12–17 2 0 Low Yes 9, 12, 15, 18, 24, 30 2.5, 3.0, 3.5, 4.0
Biodivysio AS Biocompatibles Slotted tube Stainless steel 0.091 19–25 2 4 Low No 11, 15 3.0, 3.5, 4.0
Biodivysio OC Biocompatibles Slotted tube Stainless steel 0.091 9–12 4 4 Low No 15, 18, 22, 28 3.0, 3.5, 4.0
BxVelocity/Hepacoat Cordis, Johnson & Johnson Slotted tube Stainless steel 0.14 15 2.5 1.7 Medium No 8, 13, 18, 23, 28, 32 2.25, 2.5, 2.75, 3.0,
3.5, 4.0, 4.5, 5.0
BxSonic Cordis, Johnson & Johnson Slotted tube Stainless steel 0.14 15 2.4 1.7 Medium No 8, 13, 18, 23, 28, 33 2.25, 2.5, 2.75, 3.0,
3.5, 4.0
Carbostent Sirius Sorin Slotted tube Stainless steel 0.075 12–17 3–5 0 Low Yes 9, 12, 15, 19, 25 2.5, 3.0, 3.5, 4.0
Carbostent Syncro Sorin Slotted tube Stainless steel 0.075 12–17 3–5 0 Low Yes 9, 12, 15, 19, 25 2.5, 3.0, 3.5, 4.0
Cook V-Flex Cook Slotted tube Stainless steel 0.07 15 21 0 Low No 12, 16, 20, 24 2.5, 3.0, 3.5
Diamond Flex AS Phytis Slotted tube Stainless steel 0.075 10–18 3–5 1 Low No 9, 12, 16, 20, 25 2.5, 3.0, 3.5, 4.0
JoStent Flex Jomed Slotted tube Stainless steel 0.09 16 4 5 Low No 9, 16, 26, 32 2.0, 2.5, 3.0, 3.5,
4.0, 4.5
JoStent Plus Jomed Slotted tube Stainless steel 0.09 16 4 5 Low No 9, 17, 27, 33 2.0, 2.5, 3.0, 3.5,
4.0, 4.5
JoStent Graft Jomed Slotted tube Stainless steel 0.20 100 2 3 High No 9, 12, 16, 19, 26 2.5, 3.0, 3.5, 4.0,
4.5, 5.0
LP Stent Boston Scientific Slotted tube Stainless steel 0.1 15 2 3–5 Low No 8, 12, 18, 24 2.5, 30, 3.5, 4.0
MAC Carbon Stent AMG Slotted tube Stainless steel 0.085 8–15 3 1 Low No 9, 13, 17, 22 2.0, 2.5, 3.0, 3.5,
4.0, 4.5
Megaflex Genius Eurocor Slotted tube Stainless steel 0.12 20 1 1 High No 9, 12, 13, 15, 16,
17, 19, 23
2.5, 2.75, 3.0, 3.5,
4.0
Multilink Tetra Guidant Slotted tube Stainless steel 0.091–0.124 12–20 2–3 3–4 Medium No 8, 13, 18, 23, 28 2.5, 2.75, 3.0, 3.5,
4.0
Multilink Penta Guidant Slotted tube Stainless steel 0.091–0.124 12–16 2–3 3–4 Medium No 8, 13, 15, 18, 23,
28, 33
2.75, 3.0, 3.5, 4.0
Multilink Ultra Guidant Slotted tube Stainless steel 0.127–0.101 15–25 2 5 Medium No 13, 18, 28, 38 3.5, 4.0, 4.5, 5.0
NIR, 7 cells and 9
cells
Medinol, Boston Scientific Multicell design Stainless steel 0.1 11–18 3 3 Low No 9, 16, 25, 32 2.0, 2.5, 3.0, 3.5,
4.0, 4.5, 5.0
NIR Royal Medinol, Boston Scientific Multicell design Stainless steel,
gold
0.1 11–18 5 3 High No 9, 16, 25, 32 2.0, 2.5, 3.0, 3.5,
4.0, 4.5, 5.0
Express Boston Scientific Multicell design Stainless steel,
gold
0.132 11–17 5 5 High No 8, 12, 16, 20, 24,
28, 32
2.25, 2.5, 2.75, 3.0,
3.5, 4.0, 4.5, 5.0
P-S 153 Cordis, Johnson & Johnson Slotted tube Stainless steel 0.062 18 5 8 Medium No 8, 9, 14, 18 3.0, 3.5, 4.0
PURA-A Devon Slotted tube Stainless steel 0.12 10–15 2 1–5 Low No 7, 15 3.0, 3.5, 4.0, 4.5,
5.0
PURA Vario AL Devon Slotted tube Stainless steel 0.07 10–18 3 5 Low No 6, 10, 16, 24, 28 3.5, 4.0
PURA Vario AS Devon Slotted tube Stainless steel 0.07 10–18 3 7 Low No 6, 10, 16, 24, 28 2.5, 3.0
Teneo Tenax-XR Biotronik Slotted tube Stainless steel 0.08 14–22 5 3 Low Yes 10, 15, 20, 25, 30 2.5, 3.0, 3.5, 4.0
Tsunami Terumo Slotted tube Stainless steel 0.08 18 5 5 Low No 10, 15, 20, 30 2.5, 3.0, 3.5, 4.0
Small-vessel stents
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than the stainless-steel NIR (37.5% vs. 20.6%, p  0.001),
as reported in the NIR Ultimate Gold-Gilded Equivalency
Trial (NUGGET) (26). Similar findings were reported with
a gold-coated stent manufactured by a different company
(27).
For aorto-ostial lesions with a reference vessel size of 4
mm in diameter, we have had a positive clinical experience
with the BxVelocity, the nine-cell NIR, and the Ultra. All
of these slotted-tube stents maintain good radial force, even
when dilated to large diameters.
Bifurcational lesions. When approaching a bifurcational
lesion, it may be preferable to have a stent with large side
openings between the struts that can easily permit passage of
a balloon or second stent into the side branch. Figure 4
shows several slotted-tube stents with the cross-sectional
area of the cell following stent dilation and with the
cross-sectional area of the same cell following the maximal
opening of a balloon inflated across the cell into the side
branch (28). Many slotted-tube stents are suitable for
stenting a bifurcation, with the exception of the NIR stent.
The closed-cell design of the NIR does not allow significant
expansion of the opening toward the side branch, even after
crossing and inflating a balloon. If the operator decides to
use the NIR stent, the seven-cell design should be used
instead of the nine-cell design.
Another option is to use a stent with a large side opening,
such as the Biodivysio open-cell design or the S670. The
advantage of this decision is that the initial access to the side
branch is facilitated. A possible disadvantage is incomplete
prolapse of one strut toward the side branch following a
“kissing” balloon dilation (i.e., dilating 2 balloons simulta-
neously into both branches of a bifurcation). The concept of
strut prolapse from the main branch toward the side branch
has been pioneered by Dr. Marie Claude Morice and Dr.
Tierry Lefevre and termed “stenting both branches with one
stent.” When the design is very open, there is less possibility
for a strut to straddle across the side branch. Slotted-tube
stents that best demonstrate this feature are the beStent and
Carbostent, but the BxVelocity and Tetra are also adequate
(Fig. 5).
Whichever stent the operator uses for a bifurcation, it is
important to perform a “kissing” balloon inflation at the end
of the procedure to correct the stent distortion that occurs
after balloon inflation in the side branch (29). If the
operator finds it appropriate to stent both branches, we
recommend the modified T or V techniques.
Lesions located at the left main stem. Left main stem
lesions may involve treatment of an aorto-ostial lesion
and/or a lesion located in the body of the left main artery.
Occasionally, there is a need to treat the distal left main
stem as a bifurcational lesion.
The reference size of the left main coronary artery is
favorable to stent implantation in terms of the restenosis
rate. The major problem is that in an unprotected left main
artery, stent restenosis may manifest either as sudden death
or unstable angina rapidly followed by death. For thisTa
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reason, when stent implantation in an unprotected left main
artery is clinically indicated, we frequently debulk the lesion
with directional atherectomy to minimize the risk of reste-
nosis (30).
Selection of the stent to be used depends on the issues
discussed previously concerning ostial lesions and bifurca-
tional lesions. The only unique aspect of left main stenting
is the final size of this vessel. It is not unusual, especially if
intravascular ultrasound (IVUS) is employed (31), to per-
form a post-stent dilation with a balloon 4 mm. For this
reason, when the left main artery appears large, we recom-
mend using slotted-tube stents that can be expanded 4
mm. The NIR nine-cell, BxVelocity, Tetra and Ultra are
excellent choices. When the stent is overexpanded and it is
located in the aorto-ostial position, it is important to realize
that a significant foreshortening will occur. The operator
should take this into account when initially placing the stent
by placing the proximal end of the stent 1 to 2 mm into the
aorta. In addition, if the ostium is left uncovered, the
operator should not hesitate to place a second stent. The use
of IVUS may be beneficial in determining the precise
position of a stent. The use of stents with no foreshortening
and with markers like the beStent or Carbostent is an
important consideration in this context. As a general rule,
when treating an aorto-ostial lesion, it is important to avoid
using a stent that is very short, such as an 8- or 9-mm stent.
This recommendation becomes even more important
when dealing with a lesion at the ostium of the left main
artery. We have seen stents ejected from the left main
stem at the time of postdilation due to their short
anchoring length.
Calcified lesions. Despite the widespread notion that cal-
cium affects stent expansion (32), there are only a few
reports specifically dealing with this issue (33,34). The
general view is that stent expansion in a calcified lesion will
yield a smaller final lumen than will expansion in a non-
calcified lesion. Adequate final expansion is usually achieved
by stretching the non-calcified arc of the vessel. If an
adequate final lumen size is achieved, this approach does not
seem to affect restenosis. To obtain an adequate final lumen
size, it is important to have a slotted-tube stent with
minimal recoil and good radial strength. The NIR, BxVe-
Table 2. Crossing Profile
Product Manufacturer
Crossing Profile*
2.5-mm Diameter 3.0-mm Diameter
AVE S670 Medtronic 1.09
AVE S660 Medtronic 0.99
beStent 2 Medtronic 1.07 1.17
Biodivysio AS Biocompatibles 1.07
Biodivysio SV Biocompatibles 0.84
BxVelocity Cordis, Johnson & Johnson 1.07 1.17
BxSonic Cordis, Johnson & Johnson 1.07 1.14
Carbostent Sorin 1.02 1.04
Multilink Tetra Guidant ACS 1.04 1.12
Multilink Penta Guidant ACS 1.04 1.07
Multilink Pixel Guidant ACS 0.93
NIR with sox Medinol, Boston Scientific 1.09 1.12
Express Boston Scientific 1.02 1.09
*Data presented reflect measurements performed by individual manufacturers; the method used to measure and the exact site of
measurements may differ among different stents.
Figure 1. (A) Baseline angiogram of a lesion (arrow) in the proximal right coronary artery. (B) Angiogram after implantation of a nine-cell, 16-mm-long
NIR stent. The hinge site at the end of the stent is clear (arrow).
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locity, Tetra, and AVE-S family stents are all reasonable
choices.
In calcified lesions, the most important part of the
procedure is adequate preparation of the lesion before stent
implantation. The amount of calcium visible on X-ray
underestimates the amount of calcium observed on IVUS.
Intravascular ultrasound can also distinguish whether the
calcium is in a superficial or deep location (35). Efforts to
evaluate the lesion and to prepare the implantation site with
rotational atherectomy or by cutting the balloon will be well
rewarded. Post-dilation with a short, non-compliant bal-
loon is another important step.
Chronic total occlusions. Stent implantation for chronic
total occlusions must address two problems: 1) the amount
of plaque mass in these types of lesions is large; and 2) it is
not rare that passage through the occluded segment occurs
by creating a false lumen with reentry.
These two elements mandate the insertion of a stent with
good lesion coverage and radial support. The Palmaz-
Schatz stent was used in the Stenting In Chronic Coronary
Occlusion (SICCO) study (36), which reported a significant
benefit of stent implantation (32% restenosis) in comparison
with percutaneous transluminal coronary angioplasty
(PTCA) (74% restenosis) after recanalization of chronic
total occlusions. In TOSCA (15), 410 patients with non-
acute native coronary occlusions were randomized to PTCA
or primary stenting with the heparin-coated Palmaz-Schatz
stent. With 95.6% angiographic follow-up, primary stenting
resulted in a 44% reduction in failed patency (10.9% vs.
19.5%, p  0.024) and a 45% reduction in clinically driven
target vessel revascularization at six months (8.4% vs. 15.4%,
p  0.03).
In addition to various slotted-tube stents (e.g., NIR,
BxVelocity), the Wallstent needs to be considered for
dealing with a large vessel, especially for the right coronary
artery (37).
The general rule for treating a chronic total occlusion is to
use a stent with good plaque coverage with a closed-cell
design, allowing minimal plaque prolapse in this setting
where there is a large plaque burden.
Figure 2. Four-month follow-up angiogram of the lesion in Figure 1,
showing restenosis at the hinge site (arrow).
Figure 3. Length of balloon protrusion for commonly used stents.
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Vessels smaller than 3.0 mm in diameter. Stent implan-
tation in small vessels is associated with a number of
problems. Initially, no stents were specifically made to be
expanded in small vessels with the capacity to gain optimal
radial support at diameters between 2.5 and 3.0 mm. Only
recently have stents become available such as the Mini
Crown, beStent (4 crowns), Biodivysio SV (small vessels),
six-cell BxVelocity, Multilink Pixel, 2.5-mm Carbostent
four-cell, and small-vessel Pura Vario AS, which are de-
signed to fit vessels 3 mm. The most important attributes
of these stents are their improved flexibility, capacity to
reach distal lesions, and very thin strut structure.
The recent introduction of stents specifically designed for
small vessels has allowed the performance of randomized
trials without interference from the implantation of stents
not dedicated to small vessels. Figure 6 summarizes the
results of four recently completed studies (38–41). In three
of them, the beStent-4 crown (Medtronic AVE) was used;
Figure 4. Area of the stent cell at nominal (solid bars) and maximal (open bars) expansion for several slotted-tube stents.
Figure 5. Examples of stent strut prolapse from the main branch toward the side branch after “kissing” balloon inflation (arrows). (A) The Sorin Sirius
Carbostent (Sorin Biomedica Cardio, Saluggia, Italy). (B) The beStent 2 (Medtronic AVE, Minneapolis, Minnesota). (C) The BxVelocity (Cordis, a
Johnson & Johnson Company, Warren, New Jersey). (D) The Multilink Tetra stent (Guidant, Temecula, California).
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in the other study, the Multilink was initially implanted and
then substituted by the Duet (Guidant). In two studies, the
results showed a superiority of stenting over PTCA, and in
the other two studies, the restenosis rates were equivalent.
An interesting observation came from the Intracoronary
Stenting and Angiographic Results: Strut Thickness Effect
on REstenosis Outcome (ISAR-STEREO) study (42). The
authors reported a significantly lower restenosis rate in
vessels larger than 2.8 mm (15.0% vs. 25.8%, p  0.003)
after implantation of the thin-strut (0.05 mm) Multilink
stent, compared with the thicker strut (0.14 mm) Duet
stent. Whether this finding also applies to small vessels
needs to be evaluated.
To ensure more flexibility and easier delivery to lesions
located in small vessels, we use dedicated small-vessel stents
with thin struts. The Biodivysio SV and beStent (4 crowns)
stents are probably the most suitable stents to be implanted
on lesions located in small vessels. The stent delivery system
of these stents is about 0.75 mm in profile, making them the
smallest profile stent delivery system. The Sorin Carbostent
is another thin-strut stent available in a small vessel size. All
of these stents, with the exception of the Biodivysio SV
stent, are visible under X-ray thanks to distal and proximal
radiopaque markers.
The BxVelocity, with the dedicated six-cell stent, and the
Multilink Pixel, a new, small-vessel stent by Guidant, are
also good choices. In comparison to the other small-vessel
stents, these two stents do not have thin struts and are
visible under X-ray.
Saphenous vein grafts. Implanting stents in lesions lo-
cated in a saphenous vein graft usually involves dealing with
a lesion located in a large vessel. Because a major goal is to
minimize trauma to the plaque and give maximal lesion
coverage to avoid the risk of distal embolization, self-
expandable stents are very useful in this setting. The
Wallstent or nitinol NIR stent is suitable, especially for long
lesions in these locations.
One persisting problem with stent implantation in vein
grafts is that future events may result from progression of
other lesions that were not considered critical at the time of
initial stent implantation in the target lesion (43). This issue
will be evaluated by prospective studies comparing a strategy
of focal stent implantation in the critical lesions with a
strategy aimed at implanting stents also in lesions that are
not angiographically critical.
Vein graft stent implantation must be performed with a
stent that provides optimal lesion coverage and is available
in different lengths (vein grafts require longer stents).
Other suitable stents for operators who prefer balloon-
expandable stents are the Ultra version of the Multilink
design specifically made for vein graft lesions (Guidant) and
the nine-cell NIR stent.
The most important issue concerning stenting of vein
grafts is the risk of distal embolization. Our experience is
that no particular currently available stent is more likely
than another to limit these complications. The recent
introduction of a protective balloon on a wire system (in the
Saphenous vein graft Angioplasty Free of Emboli [SAFE]
[44,45] and the Saphenous vein graft Angioplasty Free of
Emboli Randomized [SAFER] [46] studies) and a number
of filter devices has improved the safety of vein graft
interventions.
A discussion of vein graft stenting would not be complete
without mentioning the PTFE-covered stent. This device
has the potential to entrap the friable plaque present in vein
grafts, with a positive impact on distal embolization and late
restenosis (47,48). A similar device, with the covering
membrane made of bovine pericardium, is currently under
clinical evaluation (Fig. 7).
Figure 6. Restenosis rates in randomized trials of small-vessel stenting versus balloon PTCA. beSMART BEstent in SMall ARTeries; SISA Stenting
In Small Arteries; RAP  Restenosis en Arterias Pequenas; ISAR-SMART  Intracoronary Stenting or Angioplasty for Restenosis reduction in SMall
ARTeries; PTCA  percutaneous transluminal coronary angioplasty.
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Early and threatened closure. Stents were initially devel-
oped to treat acute closure from balloon dilation (49,50).
The stents used most extensively were the Gianturco-
Roubin I stent (51,52) and the Palmaz-Schatz stent (53).
Higher rates of success, even in lesions of complex anatomy
and long dissections, were reported with the Gianturco-
Roubin II stent and with the AVE II MicroStent (54).
The ideal stent for treating a dissection with impending
closure should have an easy and predictable delivery, even
without an optimal guiding catheter or guidewire support.
We have nicknamed this condition “the panic stent.” The
Pixel, the Sonic, and the S660 are some of the most
deliverable stents in complex anatomies.
Treatment of dissections may require placing a short stent
distal to an already deployed stent, usually to treat a residual
distal dissection not evident at the time of the first stent
implantation. An incompletely sealed dissection, especially
in the setting of impending closure, remains one important
predictor of stent occlusion, even with the use of high-
pressure dilation after stent implantation and with admin-
istration of aspirin and ticlopidine (55). Therefore, a stent
with a predictable delivery and with which the operator feels
confidence, is likely to be the preferred one. It will also
result in a low incidence of stent thrombosis if it provides
good coverage of the dissection without plaque prolapse.
Special situations. There are instances in which the oper-
ator needs to creatively modify the tools available to provide
a new device capable of satisfying an unusual condition.
Three of these situations are the treatment of severe focal
aneurysmal dilation of a coronary artery, diffuse aneurysmal
disease of vein grafts, and, occasionally, coronary perfora-
tions. The use of an autologous vein graft–coated stent is an
interesting solution pioneered by Stefanadis et al. (56,57).
The Tetra, BxVelocity, NIR, and other slotted-tube stents
are good platforms on which the autologous vein can be
mounted.
Coronary perforations are rare but need a rapid and
effective treatment. The new PTFE-covered stent is now
available in a premounted form and is probably the best
device to treat a coronary perforation (58) or a coronary
aneurysm (59,60).
Another use for this covered stent is the treatment of
aorto-ostial coronary and ostial saphenous vein graft lesions.
Because of the high incidence of repeat restenosis in
aorto-ostial lesions, the PTFE-covered stent should be
considered among the options, even at the time of the first
percutaneous procedure.
Drug-eluting stents. The goal of maximizing lumen gain
with mechanical scaffolding to prevent acute and chronic
recoil and to seal any dissection, coupled with the possibility
to eliminate excessive tissue proliferation, gave birth to
drug-eluting stents. As of early 2002, all drug-eluting stents
are still investigational devices. Soon, some of them will
become available for clinical use in Europe and outside the
U.S.
Drug-eluting stents can be classified according to the
specific stent design, presence or absence of a polymer to
absorb the drug, type of polymer, type of drug, and release
pattern.
Currently, the V-Flex Plus coronary stent (Cook) and the
Achieve coronary stent system (manufactured by Cook and
distributed by Guidant) are used to deliver paclitaxel ad-
hered to the stent surface with no polymer. The JoMed
coronary stent graft and the JoMed Flex (nanoporous
ceramic coating) are also used with no polymer to deliver
tacrolimus.
Stents that employ a polymer carrier for local drug
delivery are the BxVelocity (Cordis) for sirolimus; the NIR
Conformer (Medinol and Scimed) and the Express (Boston
Scientific) for paclitaxel; the Biodivysio Matrix LO (Bio-
compatibles) for dexamethasone, prednisolone, batimastat,
estrogen, and angiopeptin; the Tetra (Guidant) for actino-
mycin D; the AVE S7 (Medtronic AVE) for c-myc anti-
sense (resten-NG); and the Tsunami (Terumo Co., Tokyo,
Japan) for statins. All of the aforementioned drug-eluting
stents are in clinical trials with different degree of progress,
with the exception of resten-NG, which has not yet been
evaluated in humans. Recently, the actinomycin D and
batimastat programs have been discontinued because of a
lack of efficacy.
The drug-eluting stent programs under more advanced
clinical evaluation are the Cypher (sirolimus) and Taxus
(paclitaxel). The most important achievements of the
Cypher program are: 1) a 0% rate of six-month angio-
graphic restenosis in the RAndomized study with the
sirolimus-eluting Bx VELocity balloon-expandable stent in
the treatment of patients with de novo native coronary
artery lesions (RAVEL) trial and sustained clinical efficacy
at one-year follow-up (61); 2) persistent good vessel patency
at two-year follow-up in the First-In-Man study (62); 3) a
low 30-day event rate in the U.S. multicenter, randomized,
double-blind study of SIRolImUS-eluting stent in coronary
lesions (SIRIUS) trial (63); 4) completion of a pilot in-stent
restenosis study (64); 5) bifurcational and small vessels with
long lesions (European SIRIUS [E-SIRIUS]), projects with
Figure 7. A stent with the covering membrane made of bovine pericar-
dium.
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enrollment recently completed; 6) a left main stem registry
and the Arterial Revascularization Therapy Study (ARTS)
II registry, close to initiation; and 7) the first drug-eluting
stent in the market for coronary applications (expected for
April 2002).
The most important achievements of the Taxus program
are: 1) a 0% rate of six-month angiographic restenosis in the
pilot Taxus I trial (65); 2) completion of enrollment and a
low early event rate in Taxus II; and 3) acceptable incidence
of six-month major adverse cardiac events (17%, consisting
mainly of late target vessel revascularization) in the Taxus
III registry for treatment of in-stent restenosis (66).
Figure 8. Drug delivery to the vessel wall with various stent designs. The color chart corresponds to the amount of drug concentration.
Table 3. Stent Consumer’s Guide
Product Manufacturer Deliverability Scaffolding
Side-Branch
Access
Accurate
Positioning
Large
Vessels
Small
Vessels
AVE S670 Medtronic      
AVE S7 Medtronic      
Biodivysio Biocompatibles      
BxVelocity/Sonic Cordis, Johnson & Johnson      
JoStent graft Jomed   NA   0
Multilink Penta Guidant      
NIR, 7 cells and 9 cells Medinol, Boston Scientific      
NIR Royal Medinol, Boston Scientific      
Express Boston Scientific      
AVE S660 Medtronic AVE     NA 
Biodivysio SV Biocompatibles     NA 
Multilink Pixel Guidant ACS     NA 
  excellent;   very good;   good;   acceptable; 0  unsuitable; NA  not applicable.
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In the evolution of these special stents, we will also see
new stent designs made to maximize uniform drug delivery
to the vessel wall (Fig. 8).
Conclusions. Despite all of the theoretic and practical
considerations provided for selecting a particular stent to
treat a specific lesion, the individual experience and confi-
dence of the operator are paramount. No rationale for
choosing a specific stent for a specific lesion is yet supported
by randomized trials. Nonetheless, a large number of
observational studies support the views expressed in this
report.
Except for the use of a stent to prevent threatened
occlusion, stents are implanted with the intent to prevent
restenosis. The operator should strive to reach this goal
while maximizing the patient’s safety. Judicious stent selec-
tion, balloon sizing, and lesion preparation to achieve an
optimal final lumen dimension remain the most important
goals in percutaneous coronary interventions. For those
interested in seeing comparisons based on personal experi-
ence, we propose our point of view in a “consumer’s guide”
format (Table 3).
With the advent of drug-eluting stents, many of these
considerations and recommendations may be altered. In the
era of almost zero late loss, the concept of maximizing
lumen gain at the time of stent implantation may not be as
important as it appears today. The experience with drug-
eluting stents may change the technique of stenting, but one
goal that will not change and will become even more
important is the reliable delivery of the stent to the lesion.
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